{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:22:59Z","timestamp":1777418579795,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[1998,2,1]],"date-time":"1998-02-01T00:00:00Z","timestamp":886291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[1998,2]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To describe a case of behavioral changes induced by indomethacin in an elderly man with a history of senile dementia of the Alzheimer type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 92-year-old white man with a history of senile dementia of the Alzheimer type, glaucoma, and constipation was treated with indomethacin for an episode of pseudogout. After six doses of indomethacin 25 mg, the patient became very agitated, confused, and was physically and verbally aggressive to the nurses. Indomethacin was discontinued and the patient recovered after receiving haloperidol 0.5 mg\/d po over a period of 10 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Only a few cases of psychosis have been reported in the literature concerning the use of indomethacin in patients over the age of 60 years. The mechanism by which indomethacin causes psychosis is not well understood, but it is postulated that the acute psychosis may be related to the similarity between the molecular structure of indomethacin and serotonin. Both indomethacin and serotonin have an indolic moiety, which may explain the development of acute psychosis in this patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Healthcare providers should be aware that patients with a history of dementia who are receiving indomethacin may be at risk of developing severe behavior problems along with gastrointestinal and renal adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJETIVO:<\/jats:title>\n                    <jats:p>Informar un caso de cambios en conducta inducidos por indometacina en un envejeciente var\u00f3n con historial de demencia senil del tipo Alzheimer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESUMEN DEL CASO:<\/jats:title>\n                    <jats:p>Un hombre blanco de 92 a\u00f1os con historial de demencia senil del tipo Alzheimer, glaucoma, y constipaci\u00f3n fue tratado con indometacina para un episodio de pseudogota. Despu\u00e9s de seis dosis de indometacina de 25 mg, el paciente se puso bien agitado, confuso, y f\u00edsica y verbalmente agresivo con las enfermeras. Indometacina fue descontinuada y el paciente se recuper\u00f3 con una dosis de haloperidol 0.5 mg oral diario por un per\u00edodo de 10 d\u00edas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSI\u00d3N:<\/jats:title>\n                    <jats:p>Solo algunos casos de psicosis han sido reportados en la literatura con el uso de indometacina en pacientes sobre 60 a\u00f1os. El mecanismo por el cual indometacina produce la psicosis no es bien comprendido pero se cree que la psicosis aguda puede estar relacionada a la similaridad de la estructura molecular de indometacina y serotonina. Tanto la indometacina y serotonina tienen un componente ind\u00f3lico que podr\u00eda explicar el desarrollo de psicosis aguda en \u00e9ste paciente.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONES:<\/jats:title>\n                    <jats:p>Los proveedores de cuidado de la salud deben estar concientes que los pacientes con historial de demencia que est\u00e1n recibiendo indometacina podr\u00edan desarrollar severos problemas de conducta asi como efectos secundarios gastrointestinal y renal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIF:<\/jats:title>\n                    <jats:p>D\u00e9crire le cas d'une personne \u00e2g\u00e9e pr\u00e9sentant avec des troubles de comportement suite \u00e0 la prise d'indom\u00e9thacine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>R\u00c9SUM\u00c9 DU CAS:<\/jats:title>\n                    <jats:p>Un homme blanc de 92 ans pr\u00e9sentant avec une histoire de d\u00e9mence de type Alzheimer, de glaucome, et de constipation a \u00e9t\u00e9 trait\u00e9 avec de l'indom\u00e9thacine 25 mg trois fois par jour pour un \u00e9pisode de pseudogoutte. Apr\u00e8s 2 jours de traitement avec l'indom\u00e9thacine, \u00e0 raison de 25 mg trois fois par jour, le patient a pr\u00e9sent\u00e9 avec de l'agitation et de la confusion. Il est devenu agressif physiquement et verbalement envers le personnel infirmier. L'indom\u00e9thacine a \u00e9t\u00e9 discontinu\u00e9 et le patient a re\u00e7u de haloperidol 0.5 mg chaque jour pour une p\u00e9riode de 10 jours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Seulement quelques cas de psychose induite par l'indom\u00e9thacine ont \u00e9t\u00e9 rapport\u00e9s dans la litt\u00e9rature chez des patients de plus de 60 ans. Le m\u00e9canisme d'action par lequel la psychose se manifeste n'est pas encore bien \u00e9lucid\u00e9. Il a \u00e9t\u00e9 postul\u00e9 que la psychose serait associ\u00e9e \u00e0 la similarit\u00e9 dans les structures chimiques de lindom\u00e9thacine et la s\u00e9rotonine. La mol\u00e9cule de l'indom\u00e9thacine et celle de la s\u00e9rotonine poss\u00e8dent un groupe indolique, ce qui pourrait expliquer le d\u00e9veloppement d'une psychose aigu\u00eb.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Il est important de surveiller les changements de comportement chez les patients souffrant de d\u00e9mence lorsque l'indom\u00e9thacine est prescrit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.17203","type":"journal-article","created":{"date-parts":[[2004,3,11]],"date-time":"2004-03-11T17:08:19Z","timestamp":1079024899000},"page":"201-203","source":"Crossref","is-referenced-by-count":19,"title":["Indomethacin-Induced Behavioral Changes in an Elderly Patient with Dementia"],"prefix":"10.1177","volume":"32","author":[{"given":"Louise","family":"Mallet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jirair","family":"Kuyumjian","sequence":"additional","affiliation":[{"name":"Jirair Kuyumjian MD, Division of Geriatrics, McGill University Health Center; and Clinical Lecturer, Faculty of Medicine, McGill University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1998,2,1]]},"reference":[{"key":"bibr1-aph.17203","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6093.994-a"},{"key":"bibr2-aph.17203","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6104.49"},{"key":"bibr3-aph.17203","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198202000-00010"},{"key":"bibr4-aph.17203","first-page":"395","volume":"58","author":"Bessa O","year":"1994","journal-title":"Conn Med"},{"key":"bibr5-aph.17203","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198305000-00042"},{"key":"bibr6-aph.17203","first-page":"349","volume":"95","author":"Spittle BJ","year":"1982","journal-title":"N Z Med J"},{"key":"bibr7-aph.17203","first-page":"617","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Insel PA","year":"1995","edition":"9"},{"key":"bibr8-aph.17203","unstructured":"Semla TP, Beizer JL, Higbee MD, eds. Geriatric dosage handbook 1997\u20131998. 3rd ed. Hudson, OH: Lexi-Comp Inc., 1997:440."},{"key":"bibr9-aph.17203","unstructured":"AHFS drug information 97. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 1997:1508."},{"key":"bibr10-aph.17203","unstructured":"Drug evaluations annual 1994. Chicago: American Medical Association, 1994:39\u201350."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.17203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.17203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:03Z","timestamp":1777374423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.17203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,2]]}},"alternative-id":["10.1345\/aph.17203"],"URL":"https:\/\/doi.org\/10.1345\/aph.17203","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,2]]}}}